StockData

IDEAYA Biosciences vs Syndax Pharmaceuticals

IDYA and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IDYA and SNDX compare

IDEAYA Biosciences is the larger company, worth 3.2 times as much as Syndax Pharmaceuticals ($2.6B against $822M).

Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −74.8% at IDEAYA Biosciences.

IDEAYA Biosciences scores higher on the StockData Score (10 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIDYASNDX
Size and price
Market cap$2.6B$822M
Share price$27.40$9.20
Change, 1 year−14.7%−44.6%
Change, 5 years15.1%−44.2%
Beta (5Y)1.111.72
Employees145298
StockData Score
Total score10 (better)3
Valuation score11
Growth score11
Performance score2 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/S11.3×2.8× (better)
P/B2.2×–
FCF yield−4.3%–
Fair value$29.50–
Margin of safety7.1%–
Growth
Revenue growth (TTM)–160%
Revenue growth, 5Y average62.1%158% (better)
Profitability
Operating margin−92.7%−61.7% (better)
Net margin−74.8%−72.3% (better)
FCF margin−48.6%–
Return on equity−16.2% (better)−426%
Return on invested capital−51.9%–
Financial health
Debt / equity0.00–
Interest coverage–−44660.0×
Current ratio10.45 (better)4.69
Altman Z-score13.65 (better)−2.30
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions106%121%
Held by insiders0.83%1.8%
Insider net buying, 12 months$281K (better)−$2.9M
Short interest, % of float8.6%21.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.